Last edition
News about "litifilimab"
FDA Grants Breakthrough Therapy Designation to Biogen's Litifilimab for Cutaneous Lupus
Biogen’s investigational monoclonal antibody litifilimab receives FDA Breakthrough Therapy designation, marking a major step toward targeted treatment for cutaneous lupus erythematosus.
Litifilimab | 29/01/2026 | By News Bureau
Royalty Pharma Signs R&D Funding Agreement with Biogen
Litifilimab is currently in Phase 3 trials for both SLE and CLE with results expected between 2026 and 2027.
Litifilimab | 13/02/2025 | By Aishwarya | 244
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy